izpis_h1_title_alt

Neintervencijsko spremljanje učinkovitosti in varnosti olanzapina (Zolrixr) v zdravljenju shizofrenije in bipolarne manije
Bon, Jurij (Author), Barbič-Žagar, Breda (Author), Bevec, Matevž (Author)

URLURL - Presentation file, Visit http://www.medrazgl.si/e107_plugins/simple_content/scontent.php?Arhiv+%C5%A1tevilk.2011%2F1 New window

Abstract
Shizofrenija in bipolarna motnja sta duševni motnji, ki v svetu predstavljata pomemben javnozdravstveni problem, ki ga je z dovolj zgodnjim odkrivanjem in zdravljenjem mogoče razmeroma dobro obvladovati in nadzorovati. V želji izboljšati učinkovitost in varnost zdravljenja z antipsihotiki se z razvojem antipsihotikov druge generacije povečuje možnost za izbiro ustreznega oz. optimalnega zdravila ter tako omogoča učinkovito zdravljenje ob zmanjšani jakosti in pogostnosti neželenih učinkov. Izvedli smo neintervencijsko preizkušanje, v katerem je 163 bolnikov s shizofrenijo in bipolarno manijo jemalo olanzapin v obliki navadnih in orodisperzibilnih tablet (Zolrixr/Zolrixr orodisperzibilne tablete, Krka, d.d., Novo mesto). Zdravljenje s povprečnim odmerkom olanzapina 12,7 mg je zmanjšalo izraženost simptomov pri 79 % bolnikov, 41 % bolnikov je bilo zaradi izboljšanja simptomov le še mejno bolnih ali celo brez znakov bolezni. Bolniki so olanzapin zelo dobro prenašali. Le 25,2 % bolnikov je imelo med spremljanjem neželene učinke, ki so jih povezovali z zdravilom, ob koncu spremljanja pa le še 17,8 %. Neintervencijsko preizkušanje je pokazalo, da je najpogostejši neželeni učinek povečanje telesne teže, prisoten le pri 11 % bolnikov, zdravljenih z olanzapinom.

Language:Slovenian
Keywords:shizofrenija, zdravljenje, olanzapin, bipolarna manija, orodisperzibilne tablete, varnost
Work type:Not categorized (r6)
Tipology:1.04 - Professional Article
Organization:FFA - Faculty of Pharmacy
Year:2011
Number of pages:str. 97-99
Numbering:Letn. 50, št. 1
UDC:616.89
ISSN on article:0025-8121
COBISS.SI-ID:2976113 Link is opened in a new window
Views:356
Downloads:135
Metadata:XML RDF-CHPDL DC-XML DC-RDF
 
Average score:(0 votes)
Your score:Voting is allowed only to logged in users.
:
Share: Bookmark and Share

Record is a part of a journal

Title:Medicinski razgledi
Shortened title:Med. razgl.
Publisher:Medicinski razgledi
ISSN:0025-8121
COBISS.SI-ID:3390978 New window

Secondary language

Language:English
Title:Post-authorization safety and efficacy study of olanzapine (Zolrix) in the treatment of shizophrenia and bipolar mania
Abstract:
Schizophrenia and bipolar disorder are mental disorders that pose a real problem to the public health care system. Early diagnosis and treatment is instrumental in a relatively good management and control of these two diseeses. Second-generation antipsychotics increase the likelihood of selecting the right, optimal medicine, which enablcs effeceive treatment at reduced strength and frequency of adverse reactions. We conducted a post authorisation study in which 163 patients with schizophrenia and bipolar maniareceived olanzapine in the form of regular and orodispersible tablets (Zolrix / Zolrix orodispersible tablets, Krka, d. d., Novo mesto). Treatment with an average dose of 12.7 mg of olanzapine reduccd symptom expression in 79% of patients. Dueto improvement in symptoms 41%, of patients became only marginally ill or even symptom-free Olanzapine was very well tolerated by patients. Only in 25% of patients medicine-related adverse reactions were noted during monitoring, while at the end of monitoring the number feel to 17.8%. The post-authorisation study showed that the most frequent adverse reaction was weight gain, which was present in only 11% of patients treated with olanzapine.


Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Comments

Leave comment

You have to log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back